Industry Responds to UK Government’s Approach to Future Relationship with EU
ABPI has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU).
The Association of the British Pharmaceutical Industry (ABPI) has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU).
In the published document, which was presented to parliament by the prime minister, the government has specified that it will seek to establish a future relationship with the EU that will not only benefit the UK but also strengthen the Union. However, the document also clearly states that there will be no extension to the transition period that has been provided for the withdrawal agreement.
“The government has set out a vision for a future relationship where both sides can work together in the interest of patient safety, public health, and the pursuit of scientific progress for UK and EU citizens,” said Richard Torbett, chief execuq of ABPI in a Feb. 27, 2020 press release. “As negotiations get underway, we urge ambition and pragmatism to achieve these goals.”
Specific areas of the government’s approach that were welcomed by the pharma industry include an annex on medicinal products, participation with Horizon Europe, and continued cooperation to prevent antimicrobial resistance. More information can be found on ABPI’s website and in the government document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
